uniQure, Replimune climbs after FDA Commissioner Makary resigns

U.S.-listed shares of Dutch gene therapy developer uniQure UQ1.F, QURE.O rise 2.6% to $29.85 premarket, following a 5% gain on Tuesday

Marty Makary resigned as U.S. FDA commissioner, President Donald Trump said on Tuesday, after weeks of clashes with the White House and health advisers

Makary faced tensions with drugmakers, including disputes with UniQure over regulatory decisions

He "was not industry‑friendly," notably after public criticism of QURE data - Truist analyst Danielle Brill

Makary also drew criticism after declining to approve a cancer treatment from Replimune REPL.O, adding to industry concerns about unpredictability

Replimune shares advanced 3.9% to $4.25 before the bell

"Expect an initial positive knee‑jerk reaction from therapeutic investors to Makary's departure .... important to consider the broader ripple effects of these developments" - Brill

As of last close, QURE up 21.6%, REPL down ~58% YTD